Cargando…

Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors

Viral vectors derived from adeno-associated viruses (AAV) are widely used for gene transfer both in vitro and in vivo. The increasing use of AAV as a gene transfer vector, as well as recently demonstrated immunological complications in clinical trials, highlight the necessity to define the specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeltner, Nadja, Kohlbrenner, Erik, Clément, Nathalie, Weber, Thomas, Linden, R. Michael
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900506/
https://www.ncbi.nlm.nih.gov/pubmed/20336156
http://dx.doi.org/10.1038/gt.2010.27
_version_ 1782183625383477248
author Zeltner, Nadja
Kohlbrenner, Erik
Clément, Nathalie
Weber, Thomas
Linden, R. Michael
author_facet Zeltner, Nadja
Kohlbrenner, Erik
Clément, Nathalie
Weber, Thomas
Linden, R. Michael
author_sort Zeltner, Nadja
collection PubMed
description Viral vectors derived from adeno-associated viruses (AAV) are widely used for gene transfer both in vitro and in vivo. The increasing use of AAV as a gene transfer vector, as well as recently demonstrated immunological complications in clinical trials, highlight the necessity to define the specific activity of vector preparations beyond current standards. In this report, we determined the infectious, physical and genome-containing particle titers of several wild-type AAV type 2 (wtAAV2) and recombinant AAV type 2 (rAAV2) preparations that were produced and purified by standard methods. We found that the infectivity of wtAAV2 approaches a physical-to-infectious particle ratio of one. This near-perfect physical-to-infectious particle ratio defines a “ceiling” for the theoretically achievable quality of recombinant AAV vectors. In comparison, for rAAV2, only approximately 50 out of 100 viral particles contained a genome and more strikingly only approximately one of the 100 viral particles was infectious. Our findings suggest that current strategies for rAAV vector design, production and/or purification should be amenable to improvements. Ultimately, this could result in the generation of near-perfect vector particles, a prospect with significant implications for gene therapy.
format Text
id pubmed-2900506
institution National Center for Biotechnology Information
language English
publishDate 2010
record_format MEDLINE/PubMed
spelling pubmed-29005062011-01-01 Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors Zeltner, Nadja Kohlbrenner, Erik Clément, Nathalie Weber, Thomas Linden, R. Michael Gene Ther Article Viral vectors derived from adeno-associated viruses (AAV) are widely used for gene transfer both in vitro and in vivo. The increasing use of AAV as a gene transfer vector, as well as recently demonstrated immunological complications in clinical trials, highlight the necessity to define the specific activity of vector preparations beyond current standards. In this report, we determined the infectious, physical and genome-containing particle titers of several wild-type AAV type 2 (wtAAV2) and recombinant AAV type 2 (rAAV2) preparations that were produced and purified by standard methods. We found that the infectivity of wtAAV2 approaches a physical-to-infectious particle ratio of one. This near-perfect physical-to-infectious particle ratio defines a “ceiling” for the theoretically achievable quality of recombinant AAV vectors. In comparison, for rAAV2, only approximately 50 out of 100 viral particles contained a genome and more strikingly only approximately one of the 100 viral particles was infectious. Our findings suggest that current strategies for rAAV vector design, production and/or purification should be amenable to improvements. Ultimately, this could result in the generation of near-perfect vector particles, a prospect with significant implications for gene therapy. 2010-03-25 2010-07 /pmc/articles/PMC2900506/ /pubmed/20336156 http://dx.doi.org/10.1038/gt.2010.27 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Zeltner, Nadja
Kohlbrenner, Erik
Clément, Nathalie
Weber, Thomas
Linden, R. Michael
Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
title Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
title_full Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
title_fullStr Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
title_full_unstemmed Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
title_short Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
title_sort near-perfect infectivity of wild-type aav as benchmark for infectivity of recombinant aav vectors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900506/
https://www.ncbi.nlm.nih.gov/pubmed/20336156
http://dx.doi.org/10.1038/gt.2010.27
work_keys_str_mv AT zeltnernadja nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors
AT kohlbrennererik nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors
AT clementnathalie nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors
AT weberthomas nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors
AT lindenrmichael nearperfectinfectivityofwildtypeaavasbenchmarkforinfectivityofrecombinantaavvectors